[1]孙利娟.左炔诺孕酮宫内节育系统联合屈螺酮炔雌醇片在子宫腺肌症中的应用[J].医学信息,2025,38(13):103-107.[doi:10.3969/j.issn.1006-1959.2025.13.019]
　SUN Lijuan.Application of Levonorgestrel-releasing Intrauterine System Combined with Drospirenone Ethinyl Estradiol Tablets in Adenomyosis[J].Journal of Medical Information,2025,38(13):103-107.[doi:10.3969/j.issn.1006-1959.2025.13.019]
点击复制

左炔诺孕酮宫内节育系统联合屈螺酮炔雌醇片在子宫腺肌症中的应用()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年13期
页码:
103-107
栏目:
论著
出版日期:
2025-07-01

文章信息/Info

Title:
Application of Levonorgestrel-releasing Intrauterine System Combined with Drospirenone Ethinyl Estradiol Tablets in Adenomyosis
文章编号:
1006-1959（2025）13-0103-05
作者:
孙利娟
天津港口医院妇产科，天津 300456
Author(s):
SUN Lijuan
Department of Obstetrics and Gynecology, Tianjin Port Hospital, Tianjin 300456, China
关键词:
左炔诺孕酮宫内节育系统; 屈螺酮炔雌醇片; 子宫腺肌症
Keywords:
Levonorgestrel-releasing intrauterine system;  Drospirenone ethinyl estradiol tablets;  Adenomyosis
分类号:
R725.6
DOI:
10.3969/j.issn.1006-1959.2025.13.019
文献标志码:
A
摘要:
目的 观察左炔诺孕酮宫内节育系统联合屈螺酮炔雌醇片在子宫腺肌症中的应用效果。方法 择取2021年1月-2023年6月于天津港口医院就诊的80例子宫腺肌症患者为研究对象，按照随机数字表法将其分为对照组与研究组，每组40例。对照组口服屈螺酮炔雌醇片治疗，研究组在对照组基础上应用左炔诺孕酮宫内缓释系统治疗，对两组临床疗效、卵巢功能[抗苗勒管激素（AMH）、促卵泡激素（FSH）、促黄体生成激素（LH）、雌二醇（E2）]、血管内皮生长因子（VEGF）、子宫及月经情况（子宫内膜厚度、子宫体积、痛经程度、月经量）、不良反应（头痛、恶心呕吐、月经紊乱）发生率进行比较。结果 研究组治疗总有效率（95.00%）高于对照组（72.50%），差异有统计学意义（P＜0.05）；两组治疗后卵巢功能指标（AMH、FSH、LH、E2）均较治疗前降低，且与对照组比较，研究组治疗后卵巢功能指标（AMH、FSH、LH、E2）更低，差异有统计学意义（P＜0.05）；两组治疗后VEGF水平均较治疗前降低，且与对照组比较，研究组治疗后VEGF水平更低，差异有统计学意义（P＜0.05）；两组治疗后子宫内膜厚度、子宫体积、痛经程度、月经量均较治疗前降低，且与对照组比较，研究组治疗后子宫内膜厚度、子宫体积、痛经程度、月经量更低，差异有统计学意义（P＜0.05）；研究组不良反应发生率（2.50%）低于对照组（17.50%），差异有统计学意义（P＜0.05）。结论 左炔诺孕酮宫内节育系统联合屈螺酮炔雌醇片在子宫腺肌症患者中的治疗效果确切，能够改善患者卵巢功能，抑制生长因子，促进疾病恢复，且安全性较高。
Abstract:
Objective To assess the application effect of levonorgestrel-releasing intrauterine system combined with drospirenone ethinyl estradiol tablets in adenomyosis. Methods Eighty patients diagnosed with adenomyosis at Tianjin Port Hospital from January 2021 to June 2023 were enrolled and allocated via random number table method into a control group (n=40) and a study group (n=40). The control group was treated with drospirenone ethinyl estradiol tablets orally, and the study group was treated with levonorgestrel intrauterine sustained-release system on the basis of the control group. The clinical efficacy, ovarian function [anti-Mullerian hormone (AMH), follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2)], vascular endothelial growth factor (VEGF), uterus and menstruation ( endometrial thickness, uterine volume, dysmenorrhea degree, menstrual volume ), and incidence of adverse reactions (headache, nausea and vomiting, menstrual disorder) were compared between the two groups. Results The total effective rate of treatment in the study group (95.00%) was higher than that in the control group (72.50%), and the difference was statistically significant (P<0.05). The ovarian function indexes (AMH, FSH, LH, E2) of the two groups after treatment were lower than those before treatment, and compared with the control group, the ovarian function indexes (AMH, FSH, LH, E2) of the study group after treatment were lower, the difference was statistically significant (P<0.05). The level of VEGF in the two groups after treatment was lower than that before treatment, and compared with the control group, the level of VEGF in the study group after treatment was lower, the difference was statistically significant (P<0.05). The endometrial thickness, uterine volume, dysmenorrhea degree and menstrual volume of the two groups after treatment were lower than those before treatment. Compared with the control group, the endometrial thickness, uterine volume, dysmenorrhea degree and menstrual volume of the study group were lower after treatment, and the difference was statistically significant (P<0.05). The incidence of adverse reactions in the study group (2.50%) was higher than that in the control group (17.50%), and the difference was statistically significant (P<0.05). Conclusion Levonorgestrel-releasing intrauterine system combined with drospirenone ethinyl estradiol tablets has a definite therapeutic effect in patients with adenomyosis, which can improve ovarian function, inhibit growth factors, promote disease recovery, and has high safety.

参考文献/References:

[1]Abbott JA.Adenomyosis and Abnormal Uterine Bleeding (AUB-A)-Pathogenesis, diagnosis, and management[J].Best Pract Res Clin Obstet Gynaecol,2017,40:68-81.[2]Qin Z,Dong Z,Tang H,et al.Application of modified subtotal resection of adenomyosis combined with LNG-IUS and GnRH-a sequential therapy in severe adenomyosis: A case series[J].Front Surg,2022,9:914725.[3]刘红玲,张保萍.止痛化癥胶囊联合左炔诺孕酮宫内节育系统治疗子宫腺肌病的临床研究[J].现代药物与临床,2022,37(9):2093-2097.[4]刘宏,郭秀荣,韩静,等.左炔诺孕酮宫内节育系统联合桂枝茯苓胶囊对子宫腺肌症患者性激素、血脂及血清hs-CRP、VEGF水平的影响[J].现代生物医学进展,2021,21(20):3965-3968,3983.[5]Ishizawa C,Hirota Y,Iida R,et al.Levonorgestrel-Releasing Intrauterine System Improves Menorrhagia-Related Quality of Life in Patients with Symptomatic Adenomyosis[J].Reprod Sci,2023,30(3):966-973.[6]庞华琴,陈君霞,阮雅文.GnRH-a联合左炔诺孕酮宫内节育系统治疗子宫腺肌症疗效及对患者卵巢功能、CA125、CA153和CEA表达的影响[J].中国基层医药,2022,29(6):825-829.[7]张文秋,谢李鑫,方秋香.屈螺酮炔雌醇注射用醋酸亮丙瑞林微球联合左炔诺孕酮宫内节育系统治疗子宫腺肌症患者的疗效评价[J].中国药物与临床,2021,21(23):3900-3903.[8]关琼,杨爱玉,吴绪峰.子宫腺肌病患者在醋酸亮丙瑞林基础上联合左炔诺孕酮宫内节育系统或地诺孕素治疗的效果比较[J].中国医药,2023,18(1):86-90.[9]裴凤霞,徐贞淑,严丽慧.左炔诺孕酮宫内节育系统联合少腹逐瘀汤加减治疗子宫腺肌病痛经临床研究[J].新中医,2020,52(8):55-57.[10]汤芝丽.小剂量米非司酮联合地屈孕酮片对子宫腺肌症患者子宫体积及痛经程度的影响[J].中国基层医药,2020,27(18):2264-2268.[11]潘鑫,李珉.散结镇痛胶囊联合屈螺酮炔雌醇片治疗子宫腺肌症对卵巢储备功能及血管生成因子水平影响[J].中国计划生育学杂志,2022,30(3):534-537,541.[12]许林敏,陈海棠,赵渊,等.GnRH-a联合屈螺酮炔雌醇片对子宫腺肌病的疗效及对肿瘤标志物的影响[J].中国计划生育学杂志,2019,27(6):776-779[13]虞蕾虹,王泽华.GnRH-a与屈螺酮炔雌醇序贯治疗对子宫腺肌瘤腔镜手术效果的影响[J].武汉大学学报(医学版),2021,42(3):429-433.[14]Joo JK,Shin JH,Lee JR,et al.Levonorgestrel-Releasing Intrauterine System Use in Perimenopausal Women[J].J Menopausal Med,2021,27(2):49-57.[15]吕萍萍.丹黄祛瘀胶囊联合左炔诺孕酮宫内节育系统对子宫腺肌病患者子宫血液流变学和趋化因子的影响[J].检验医学与临床,2021,18(20):2986-2989,2993.[16]覃卫玲,廖婕洁.注射用醋酸曲普瑞林联合左炔诺孕酮宫内节育系统对子宫腺肌病患者子宫血流动力学、卵巢功能及安全性的影响[J].中国医院用药评价与分析,2019,19(5):546-548,551.[17]陈红霞,陈霞,丁雪松,等.Ⅰ型子宫腺肌病患者放置左炔诺孕酮宫内节育系统前应用不同剂量米非司酮预处理疗效比较[J].新乡医学院学报,2021,38(12):1160-1165.[18]楼俊瑶,黄秀峰,张丽凤,等.第二代子宫内膜消融术可提高左炔诺孕酮宫内节育系统对子宫腺肌病患者的疗效[J].浙江大学学报(医学版),2019,48(2):136-141.[19]张丽凤,杨慧,张信美,等.左炔诺孕酮宫内节育系统治疗子宫腺肌病患者的疗效和不良反应观察[J].浙江大学学报(医学版),2019,48(2):130-135.[20]杜成超,蒋刘鹏,蒋静,等.聚焦超声消融手术联合子宫内膜部分切除治疗子宫腺肌病的前瞻性研究[J].中国医学装备,2021,18(8):113-117.[21]Sun F,Zhang Y,You M,et al.Laparoscopic adenomyomectomy combined with levonorgestrel-releasing intrauterine system in the treatment of adenomyosis: Feasibility and effectiveness[J].J Obstet Gynaecol Res,2021,47(2):613-620.[22]Shi JH,Zhu SY,Li XY,et al.The role of levonorgestrel-releasing intrauterine system for recurrence prevention after conservative surgery among patients with coexistent ovarian endometrioma and diffuse adenomyosis: A retrospective case control study with long-term follow up[J].J Gynecol Obstet Hum Reprod,2023,52(5):102572.[23]武富云.左炔诺孕酮宫内节育系统联合屈螺酮炔雌醇片(Ⅱ)对围绝经期异常子宫出血患者疗效研究[J].中国药物与临床,2020,20(24):4124-4126.[24]Silver S,Arnold JJ.Levonorgestrel-Releasing Intrauterine System for Regression of Endometrial Hyperplasia[J].Am Fam Physician,2021,104(1):26-27.

更新日期/Last Update: 1900-01-01